乌苯美司在晚期卵巢癌化疗中的应用  

Application of ubenimex in chemotherapy for patients with advanced ovarian cancer

作　　者：路金枝[1] 王继芳[1] 

机构地区：[1]山东淄博临淄区人民医院妇科,山东淄博255400

出　　处：《中国民康医学》2013年第13期37-39,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察乌苯美司在晚期卵巢癌化疗中对患者免疫功能的影响和对患者生活质量的作用。方法:将100例晚期卵巢癌患者随机分为对照组(40例)和治疗组(60例),两组患者均行PT方案化疗。治疗组患者加服乌苯美司30 mg qd共6个月,4个周期后评价化疗疗效和毒副反应,以化疗前和化疗6周期后患者KPS评份、体重变化评价患者的生活质量和一般体力状况。结果:4周期化疗后两组有效率分别为55%(对照组)和56.7%,无显著差异;对照组的重度骨髓抑制发生率(55%)高于治疗组(23.3%),有统计学意义;治疗组KPS评分稳定率和体重稳定率为82.8%和79.3%,而对照组为55.6%和50%,两者比较均有统计学意义。结论:乌苯美司联合化疗对晚期卵巢癌患者免疫功能有一定改善作用,减轻了毒副反应,改善了生活质量。Objective：To evaluate effects of ubenimex on immune functions and quality of life for patients with advanced ovari- an cancer receiving chemotherapy, nethods：100 patients with advanced ovarian cancer were randomly divided into treatment group （n = 60） and control group （ n = 40）, all the cases received PT chemotherapy, and the cases in treatment group took ubenimex 30 mg P. 0 daily for 6 months additionally. Chemotherapy effects and toxic and side effects were assessed 4 weeks after the treatment ; and quali- ties of life and general physical conditions were evaluated by KPS score and body weight change before and 6 weeks after the chemother- apy. Results： 4 weeks after the chemotherapy, effective rates of control group and treatment group were 55% and 56.7%, respective- ly, and difference was insignificant （P 〉 0.05 ）. Incidence rate of severe myelosuppression of control group （55%） was higher than that of treatment group （23.3%）, and the difference had the statistical significance （ P 〈 0.05 ）. Stable rates of the KPS score and body weight after the chemotherapy were 55.6% and 50% in control group, whereas those were 82.8% and 79.3% in treatment group, and the differences had the statistical significance （ all P 〈 0.05 ）. Conclusions： Ubenimex combined with chemotherapy can improve immune functions for the patients with advanced ovarian cancer, alleviate toxic and side effects, and improve the quality of life.

关 键 词：卵巢癌晚期 化学疗法 乌苯美司 毒副作用 免疫功能 生活质量 

分 类 号：R737.31[医药卫生—肿瘤]